JG
AVDL

Jefferies Group’s Avadel Pharmaceuticals AVDL Stock Holding History

Jefferies Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-26,600
Closed -$261K – 1622
2021
Q3 		$261K Sell
26,600
-5,500
-17% -$43.3K ﹤0.01% 1397
2021
Q2 		$216K Buy
+32,100
New +$255K ﹤0.01% 1395

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Jefferies Group's AVDL Position: Q1 2022 in Review

Jefferies Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2022, closing a stake of 44 shares — an estimated $356 sold.

Jefferies Group first reported a position in AVDL in Q1 2016 and held it in 2 quarters. The position peaked at $323K in Q1 2016. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2022.

  • Jefferies Group reported no remaining Avadel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jefferies Group sold 44 Avadel Pharmaceuticals shares in Q1 2022, an estimated $356.
  • Jefferies Group first reported a position in Avadel Pharmaceuticals in Q1 2016 and held it in 2 quarters.
  • Jefferies Group's Avadel Pharmaceuticals position peaked at $323K in Q1 2016.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2022.

Based on Jefferies Group's 13F filing for Q1 2022, filed 16 May 2022.